BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/10/2015 5:56:00 PM | Browse: 1653 | Download: 2168
Publication Name World Journal of Hepatology
Manuscript ID 16781
Country Türkiye
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Bulent Baran
Funding Agency and Grant Number
Corresponding Author Bulent Baran, MD, FEBG, Department of Gastroenterology, Koç University Hospital, Davutpasa St., Zeytinburnu, 34010 Istanbul, Turkey. drbulentbaran@gmail.com
Key Words Hepatitis B virus; Hepatocellular carcinoma; Prevention; Nucleos(t)ide analogues; Risk factors
Core Tip After the introduction of potent nucleos(t)ide analogues with high genetic barrier to resistance, main-taining long-term virological suppression is achievable in almost all patients with chronic hepatitis B. The currently recommended first-line antiviral drugs, entecavir and tenofovir, can significantly reduce hepatocellular carci-noma (HCC) incidence, but the observed risk under efficient therapy is not zero in the long-term. There are established risk factors including age, gender, family history, low platelet levels, presence of cirrhosis or severity of liver disease, which should be incorporated into the clinical decision making to differentiate those patients under risk of developing HCC.
Publish Date 2015-07-10 17:51
Citation Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1742-1754
URL http://www.wjgnet.com/1948-5182/full/v7/i13/1742.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i13.1742
Full Article (PDF) WJH-7-1742.pdf
Full Article (Word) WJH-7-1742.doc